A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Conditions
B-Cell Non-Hodgkin Lymphoma · Histiocytic and Dendritic Cell Neoplasm · Myelodysplastic Syndrome · Previously Treated Myelodysplastic Syndrome · Recurrent Adult Acute Myeloid Leukemia · Recurrent Anaplastic Large Cell Lymphoma · Recurrent Angioimmunoblastic T-Cell Lymphoma · Recurrent Mycosis Fungoides · Recurrent Plasma Cell Myeloma · Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma · Recurrent T-Cell Non-Hodgkin Lymphoma · Refractory Acute Myeloid Leukemia · Refractory Anaplastic Large Cell Lymphoma · Refractory Angioimmunoblastic T-Cell Lymphoma · Refractory Mycosis Fungoides · Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified · Refractory Plasma Cell Myeloma · Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma · Refractory T-Cell Non-Hodgkin Lymphoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015Contact: Principal Investigator (Nathan L. Punwani, M.D.)Mayo Clinic in Rochester, Rochester, Minnesota, United States
Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015Contact: Principal Investigator (Nora Bennani, M.D.)Contact: Principal Investigator (Joselle Cook, M.B.B.S.)
Study leads
Nora Bennani, M.D.
Principal Investigator
Mayo Clinic in Rochester
Joselle Cook, M.B.B.S.
Principal Investigator
Mayo Clinic in Rochester